Sara A Byron

Sara A Byron

UNVERIFIED PROFILE

Are you Sara A Byron?   Register this Author

Register author
Sara A Byron

Sara A Byron

Publications by authors named "Sara A Byron"

Are you Sara A Byron?   Register this Author

27Publications

809Reads

49Profile Views

Genomics-Enabled Precision Medicine for Cancer.

Cancer Treat Res 2019 ;178:137-169

Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-030-16391-4_5DOI Listing
June 2019

Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer.

Mol Oncol 2019 04 18;13(4):738-756. Epub 2019 Jan 18.

School of Biomedical Science, Institute of Health & Biomedical Innovation, Queensland University of Technology located within the Translational Research Institute, Brisbane, Australia.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/1878-0261.12
Publisher Site
http://dx.doi.org/10.1002/1878-0261.12422DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441928PMC
April 2019

FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

Gynecol Oncol 2017 05 15;145(2):366-373. Epub 2017 Mar 15.

Queensland University of Technology (QUT) at the Translational Research Institute, Brisbane, Australia; Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2017.02.031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433848PMC
May 2017

Translating RNA sequencing into clinical diagnostics: opportunities and challenges.

Nat Rev Genet 2016 May 21;17(5):257-71. Epub 2016 Mar 21.

Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona 85004, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrg.2016.10DOI Listing
May 2016

Toward precision medicine in glioblastoma: the promise and the challenges.

Neuro Oncol 2015 Aug 1;17(8):1051-63. Epub 2015 May 1.

University of California San Francisco, San Francisco, California (M.D.P, J.J.P., A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.); Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L., P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.); University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.); University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa Spine and Brain Institute, Waterloo, Iowa (T.C.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490873PMC
August 2015

Negative regulation of NF-κB by the ING4 tumor suppressor in breast cancer.

PLoS One 2012 4;7(10):e46823. Epub 2012 Oct 4.

Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, Arizona, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0046823PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464231PMC
May 2013

XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts.

Anticancer Drugs 2013 Feb;24(2):181-8

The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0b013e32835a43f1DOI Listing
February 2013

Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.

Int J Gynecol Cancer 2012 Nov;22(9):1517-26

Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00009577-900000000-994
Publisher Site
http://dx.doi.org/10.1097/IGC.0b013e31826f6806DOI Listing
November 2012

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.

Mol Cancer 2012 Oct 5;11:75. Epub 2012 Oct 5.

Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-11-75DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554420PMC
October 2012

FGFR2 mutations are rare across histologic subtypes of ovarian cancer.

Gynecol Oncol 2010 Apr 27;117(1):125-9. Epub 2010 Jan 27.

Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ 85004, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2009.12.002DOI Listing
April 2010

FGFR2 as a molecular target in endometrial cancer.

Future Oncol 2009 Feb;5(1):27-32

Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/14796694.5.1.27DOI Listing
February 2009

Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer.

Semin Oncol 2003 Oct;30(5 Suppl 16):125-32

Department of Medicine and Pharmacology, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2003.08.014DOI Listing
October 2003